Medtronic plc
MDT
$82.39
+0.46%
Medtronic plc is a global leader in medical technology, developing and manufacturing therapeutic devices for chronic diseases, including pacemakers, defibrillators, heart valves, stents, spinal implants, and surgical tools. As one of the largest medical-device companies by revenue, it holds a dominant market position across multiple therapeutic categories, with a diversified portfolio and a strong presence in the U.S., Western Europe, and Japan. The current investor narrative centers on Medtronic's growth acceleration in cardiovascular and diabetes segments, driven by new product launches like the Hugo surgical robot, while margin pressure and cautious FY2027 guidance create a mixed outlook. Recent news highlights the company's strategic acquisitions, such as the $550 million Scientia Vascular deal, and its efforts to challenge Intuitive Surgical's robotic surgery dominance.…
MDT
Medtronic plc
$82.39
Related headlines
Investment Opinion: Should I buy MDT Today?
Rating: Buy. Medtronic offers a compelling risk/reward at current levels, with a forward P/E of 12.99x implying significant undervaluation relative to its growth prospects and a 28.6% upside to the implied analyst target of $107. The consensus analyst rating is bullish, supported by strong revenue growth in cardiovascular and diabetes and a healthy balance sheet.
Supporting evidence includes: (1) forward P/E of 12.99x, near the lower end of its historical band; (2) estimated revenue growth to $46.57 billion, driven by cardiovascular and diabetes; (3) gross margin of 65.0% and operating margin of 17.8%, indicating stable profitability; (4) positive free cash flow with a PCF ratio of 14.57; and (5) a dividend yield of 3.4% with a low beta of 0.583, providing downside protection. Compared to the medical devices sector median P/E of ~18x, Medtronic's forward P/E is at a discount, suggesting undervaluation.
Key risks that could invalidate the thesis include: (1) failure to achieve EPS growth estimates, leading to multiple compression; (2) margin pressure from competitive pricing or cost inflation; and (3) slower-than-expected adoption of the Hugo robot. This Buy rating would be downgraded to Hold if the stock approaches the analyst target of $107 without new catalysts, or if revenue growth decelerates below 5%. Overall, Medtronic appears undervalued relative to its history and peers, offering a favorable entry point for long-term investors.
Sign up to view all
MDT 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Medtronic's forward valuation is attractive, with a P/E of 12.99x implying significant earnings growth. The company's strong revenue trajectory in cardiovascular and diabetes, combined with a healthy balance sheet and defensive characteristics, supports a positive outlook. However, the high PEG ratio of 6.72x and margin pressure warrant caution. The base case is most likely, with a 50% probability, targeting $85-$100. An upgrade to high confidence would require evidence of margin expansion and sustained growth, while a downgrade would follow if competitive threats intensify or growth disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Medtronic plc's 12-month outlook, with a consensus price target around $107.11 and implied upside of +30.0% versus the current price.
Average Target
$107.11
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$66 - $107
Analyst target range
Medtronic is covered by 5 analysts, with a consensus recommendation leaning bullish. The average estimated EPS is $8.23, and the average estimated revenue is $46.57 billion. The average target price is not explicitly provided, but based on the forward P/E of 12.99x and estimated EPS of $8.23, the implied target price is approximately $107 (12.99 * 8.23). Compared to the current price of $83.19, this implies an upside of +28.6%. The consensus sentiment is positive, reflecting confidence in the company's growth trajectory. The estimated EPS range is $7.71 (low) to $8.44 (high), and the revenue range is $44.34 billion to $47.49 billion. The high target assumes strong execution in cardiovascular and diabetes, successful Hugo robot adoption, and margin expansion. The low target prices in competitive pressures, slower growth in legacy segments, and persistent margin headwinds. The spread between high and low EPS estimates is about 9.4%, indicating moderate uncertainty. There is no recent institutional ratings data available, but the limited analyst coverage (5 analysts) suggests that Medtronic is a well-followed large-cap stock, and the narrow estimate range implies relatively high conviction among analysts.
Drowning in data?
Find the real signal!
Bulls vs Bears: MDT Investment Factors
Medtronic presents a mixed investment case. On the bull side, the company benefits from strong revenue growth in cardiovascular and diabetes, an attractive forward valuation with 28.6% upside to analyst targets, a healthy balance sheet, and defensive characteristics with a low beta and 3.4% dividend yield. However, bears point to the sustained downtrend, high PEG ratio of 6.72x, margin pressure, competitive threats in robotic surgery, and low trailing EPS. Currently, the bull case has slightly stronger evidence given the forward valuation discount and recent momentum, but the key tension is whether the company can deliver on growth expectations to justify the premium trailing P/E of 22.22x. If revenue growth accelerates and margins stabilize, the stock could re-rate higher; if growth disappoints, the stock may remain range-bound or decline further.
Bullish
- Strong Revenue Growth in Cardiovascular and Diabetes: Medtronic's cardiovascular and diabetes units are driving strong revenue growth, with the company reaffirming its FY2026 outlook. The cardiovascular boom is offsetting margin pressure, as highlighted in recent news, and the estimated revenue of $46.57 billion represents a solid top-line trajectory.
- Attractive Forward Valuation with 28.6% Upside: The forward P/E of 12.99x is near the lower end of its historical band, implying the stock may be undervalued. Based on the average EPS estimate of $8.23, the implied target price is ~$107, offering a 28.6% upside from the current price of $83.19.
- Healthy Balance Sheet and Strong Liquidity: Medtronic has a debt-to-equity ratio of 0.57 and a current ratio of 2.13, indicating moderate leverage and strong liquidity. The company generates positive free cash flow with a PCF ratio of 14.57, supporting its ability to invest in growth and maintain dividends.
- Defensive Characteristics with Low Beta: With a beta of 0.583, Medtronic is 41.7% less volatile than the market, making it a defensive holding. The stock offers a dividend yield of 3.4% with a payout ratio of 75.8%, appealing to income-oriented investors during market uncertainty.
Bearish
- Sustained Downtrend and Underperformance: Medtronic has declined 5.77% over the past year, significantly underperforming the S&P 500's 19.1% gain. The stock is trading at 78.2% of its 52-week range, reflecting persistent selling pressure and negative momentum.
- High PEG Ratio Suggests Limited Upside: The PEG ratio of 6.72x indicates that growth expectations are already priced into the stock. Despite a forward P/E of 12.99x, the high PEG suggests that earnings growth may not justify the current valuation, leaving limited room for multiple expansion.
- Margin Pressure and Cautious FY2027 Guidance: Recent news highlights margin pressure despite revenue growth, and the company's cautious FY2027 guidance creates uncertainty. Operating margin stands at 17.8%, and any further compression could weigh on earnings.
- Competitive Threats in Robotic Surgery: Medtronic's Hugo surgical robot faces a formidable challenge from Intuitive Surgical's dominant installed base. While FDA approval is a milestone, achieving meaningful market share will require significant investment and time.
MDT Technical Analysis
Medtronic is in a sustained downtrend over the past year, with a 1-year price change of -5.77%, significantly underperforming the S&P 500's +19.1% gain. The stock is trading at $83.19, which is 78.2% of its 52-week range (low $73.31, high $106.33), positioning it closer to the lows than the highs. This near-low positioning suggests the stock may be oversold and could offer a value opportunity, but it also reflects persistent selling pressure and negative momentum. Short-term momentum shows a sharp recovery, with a 1-month price change of +12.8%, contrasting with the 3-month decline of -3.97%. This divergence signals a potential trend reversal or a temporary bounce within a broader downtrend. The relative strength versus the S&P 500 over 1 month is +14.05%, indicating the stock is outperforming the market recently, but the 3-month relative strength is -17.53%, confirming the longer-term weakness. The 52-week low of $73.31 serves as key support; a break below would signal further downside, while the 52-week high of $106.33 is resistance. A breakout above $106.33 would indicate a reversal of the downtrend. Beta is 0.583, meaning the stock is 41.7% less volatile than the market, making it a lower-risk holding but also limiting upside participation in strong markets.
Beta
0.58
0.58x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$73-$106
Price range past year
Annual Return
-7.4%
Cumulative gain past year
| Period | MDT Return | S&P 500 |
|---|---|---|
| 1m | +0.5% | +2.0% |
| 3m | -5.5% | +10.6% |
| 6m | -15.5% | +8.3% |
| 1y | -7.4% | +20.4% |
| ytd | -14.2% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDT Fundamental Analysis
Medtronic's revenue trajectory shows growth, with the most recent quarterly revenue estimated at $46.57 billion (consensus), and the company reaffirmed its FY2026 outlook, driven by strong performance in Cardiovascular and Diabetes units. However, the multi-quarter trend indicates deceleration, as the stock has declined 13.39% year-to-date, reflecting investor concerns about growth sustainability. The cardiovascular boom is offsetting margin pressure, but the cautious FY2027 guidance suggests headwinds. The company is profitable, with a net income margin of 13.2% and a gross margin of 65.0%. Operating margin stands at 17.8%, indicating stable profitability, though margin pressure is noted in recent commentary. Net income is positive, with EPS of $0.04 (trailing twelve months), but the low EPS suggests the company is barely profitable on a per-share basis due to share count or one-time items. The balance sheet is healthy, with a debt-to-equity ratio of 0.57, indicating moderate leverage. The current ratio of 2.13 suggests strong liquidity, and the company generates positive free cash flow (PCF ratio 14.57). ROE is 9.7%, reflecting decent returns on equity, while ROA is 4.9%. The payout ratio of 75.8% is high, but the dividend yield of 3.4% is attractive for income investors. The company's financial health supports its ability to fund growth internally, though the high payout ratio limits retained earnings for reinvestment.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDT Overvalued?
Since net income is positive (EPS $0.04), the primary valuation metric is the P/E ratio. The trailing P/E is 22.22x, while the forward P/E is 12.99x, implying the market expects significant earnings growth in the next year. The gap between trailing and forward P/E suggests that the market is pricing in a recovery in earnings, which is consistent with the recent operational improvements. Compared to the industry average (medical devices), Medtronic's trailing P/E of 22.22x is at a premium to the sector median of approximately 18x, representing a 23% premium. This premium may be justified by Medtronic's diversified portfolio and market leadership, but the high PEG ratio of 6.72x suggests that the growth expectations are already priced in, leaving limited upside. Historically, Medtronic's trailing P/E has ranged between 15x and 30x over the past five years. The current 22.22x is near the middle of this range, indicating that the stock is not at extreme valuation levels. However, the forward P/E of 12.99x is near the lower end of its historical forward P/E band, suggesting that the stock may be undervalued relative to its own history if the company can deliver on growth expectations.
PE
22.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Medtronic's trailing EPS of $0.04 is extremely low, raising concerns about earnings quality and sustainability. The high payout ratio of 75.8% limits retained earnings for reinvestment, and any earnings miss could pressure the dividend. While the debt-to-equity ratio of 0.57 is manageable, the company's operating margin of 17.8% faces pressure from rising costs and competitive pricing. Revenue concentration in cardiovascular and diabetes units, which are driving growth, creates dependency on these segments; a slowdown could significantly impact overall performance.
Market & Competitive Risks: The stock's trailing P/E of 22.22x is at a 23% premium to the medical devices sector median of ~18x, making it vulnerable to valuation compression if growth disappoints. With a beta of 0.583, Medtronic is less correlated to the market, but its 1-year relative strength of -24.87% versus the S&P 500 indicates persistent underperformance. Competitive threats from Intuitive Surgical in robotics and from other medtech players in cardiovascular and diabetes could erode market share. Regulatory headwinds, such as changes in healthcare policy or reimbursement, pose additional risks.
Worst-Case Scenario: In a severe downturn, Medtronic could see its stock fall to the 52-week low of $73.31, representing a -11.9% decline from the current price of $83.19. However, if the company faces a major product recall, regulatory setback, or significant earnings miss, the stock could drop further, potentially testing the historical max drawdown of -30%, which would imply a price near $58.23. In this scenario, an investor could lose up to 30% from the current price.
FAQ
The key risks include: (1) Financial risk: low trailing EPS of $0.04 and high payout ratio of 75.8% limit reinvestment and dividend safety; (2) Competitive risk: Intuitive Surgical's dominance in robotics and competition in cardiovascular/diabetes could erode market share; (3) Valuation risk: the trailing P/E of 22.22x is at a premium to peers, making the stock vulnerable to multiple compression if growth slows; (4) Macro risk: with a beta of 0.583, the stock is less sensitive to market swings, but a recession could impact procedure volumes. The most severe risk is a sustained growth deceleration leading to a drop to the 52-week low of $73.31 or below.
The 12-month forecast is cautiously bullish. The base case (50% probability) sees the stock trading between $85 and $100, driven by steady revenue growth and stable margins. The bull case (30% probability) targets $100-$115, with catalysts from Hugo robot adoption and margin expansion. The bear case (20% probability) sees the stock falling to $73-$85, if growth disappoints or competitive pressures intensify. The most likely scenario is the base case, with the stock gradually recovering as the company executes on its growth strategy. The implied analyst target of $107 suggests a 28.6% upside from the current price of $83.19.
Medtronic appears undervalued based on forward P/E of 12.99x, which is near the lower end of its historical band and below the medical devices sector median of ~18x. However, the trailing P/E of 22.22x is at a 23% premium to the sector, reflecting the market's expectation of earnings growth. The PEG ratio of 6.72x indicates that the stock is expensive relative to its growth rate, suggesting that the market is pricing in optimistic assumptions. Overall, the stock is fairly valued to slightly undervalued on a forward basis, but the high PEG ratio warns that any growth disappointment could lead to de-rating.
Medtronic is a good buy for investors seeking a defensive, income-generating stock with upside potential. The forward P/E of 12.99x implies a 28.6% upside to the implied analyst target of $107, and the 3.4% dividend yield provides a cushion. However, the trailing P/E of 22.22x and high PEG ratio of 6.72x suggest that growth expectations are already priced in, so the stock is best suited for long-term investors who can tolerate near-term volatility. The biggest downside risk is a failure to achieve EPS growth, which could lead to multiple compression. For growth-oriented investors, the risk/reward is favorable at current levels, but for those seeking rapid gains, other options may be more suitable.
Medtronic is best suited for long-term investment, given its defensive characteristics, dividend yield, and exposure to secular growth in medical devices. With a beta of 0.583, the stock is less volatile than the market, making it a suitable core holding for conservative portfolios. The short-term momentum is positive, with a 12.8% gain in the past month, but the stock remains in a downtrend over the past year. For short-term traders, the low volatility limits potential gains, and the stock may not provide the rapid appreciation sought by active traders. A minimum holding period of 3-5 years is recommended to capture the benefits of compounding dividends and earnings growth.
